Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SERPINA6 | P08185 | 5/20 | 1.00 |
| ▸ | HSD17B10 | Q99714 | 10/20 | 0.74 |
| ▸ | NR3C1 | P04150 | 5/20 | 0.74 |
| ▸ | LMNA | P02545 | 3/20 | 0.74 |
| ▸ | TSHR | P16473 | 3/20 | 0.74 |
| ▸ | SHBG | P04278 | 3/20 | 0.74 |
| ▸ | CYP3A4 | P08684 | 3/20 | 0.74 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.74 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.74 |
| ▸ | PMP22 | Q01453 | 2/20 | 0.74 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.74 |
| ▸ | KCNA1 | Q09470 | 1/20 | 0.74 |
| ▸ | SLC47A1 | Q96FL8 | 1/20 | 0.74 |
| ▸ | HIF1A | Q16665 | 5/20 | 0.65 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.65 |
| ▸ | MEN1 | O00255 | 2/20 | 0.65 |
| ▸ | PGR | P06401 | 2/20 | 0.65 |
| ▸ | SLC29A1 | Q99808 | 1/20 | 0.65 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.65 |
| ▸ | FNTA | P49354 | 4/20 | 0.58 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Cortisone SCHEMBL9926754 | 0.85 | HSD17B10 (1.00) | SERPINA6HSD17B10NR3C1LMNATSHR | |
| Cortisone SCHEMBL10089738 | 0.85 | HSD17B10 (1.00) | SERPINA6HSD17B10NR3C1LMNATSHR | |
| Cortisone SCHEMBL13332835 | 0.85 | HSD17B10 (1.00) | SERPINA6HSD17B10NR3C1LMNATSHR | |
| Cortisone SCHEMBL4888 | 0.85 | HSD17B10 (1.00) | SERPINA6HSD17B10NR3C1LMNATSHR | |
| Cortisone SCHEMBL6535496 | 0.85 | HSD17B10 (1.00) | SERPINA6HSD17B10NR3C1LMNATSHR | |
| Cortisone SCHEMBL13026135 | 0.85 | HSD17B10 (1.00) | SERPINA6HSD17B10NR3C1LMNATSHR | |
| Cortisone SCHEMBL5082086 | 0.84 | HSD17B10 (0.98) | SERPINA6HSD17B10NR3C1LMNATSHR | |
| Cortisone SCHEMBL5082082 | 0.84 | HSD17B10 (0.98) | SERPINA6HSD17B10NR3C1LMNATSHR | |
| Cortisone SCHEMBL28537808 | 0.84 | HSD17B10 (0.98) | SERPINA6HSD17B10NR3C1LMNATSHR | |
| Cortisone SCHEMBL28542114 | 0.84 | HSD17B10 (0.98) | SERPINA6HSD17B10NR3C1LMNATSHR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 193 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120058979-A1 | METHODS AND REAGENTS FOR THE TREATMENT OF IMMUNOINFLAMMATORY DISORDERS | ZALICUS INC. (US) | 2012-03-08 | — | — | US | claimed |
| US-20120028910-A1 | STORAGE-STABLE AQUEOUS OPHTHALMIC FORMULATIONS | FOVEA PHARMACEUTICALS (FR) | 2012-02-02 | — | — | US | claimed |
| US-8080553-B2 | Methods and reagents for the treatment of immunoinflammatory disorders | ZALICUS INC. (US) | 2011-12-20 | — | — | US | claimed |
| EP-2301628-A1 | Methods and reagents for the treatment of immunoinflammatory disorders | Zalicus Inc. (US) | 2011-03-30 | — | — | EP | claimed |
| EP-2070550-A1 | Use of combinations comprising a corticosteroid and a pyrimidopyrimidine in the treatment of inflammatory diseases | Combinatorx, Incorporated (US) | 2009-06-17 | — | — | EP | claimed |
| US-20070010502-A1 | Methods and reagents for the treatment of immunoinflammatory disorders | COMBINATORX INC. (US) | 2007-01-11 | — | — | US | claimed |
| US-20260124244-A1 | MEGAKARYOCYTE DERIVATIVES FOR TREATMENT OF DRY EYE DISEASES | STELLULAR BIO, INC. (US) | 2026-05-07 | — | — | US | disclosed |
| EP-4646217-A1 | MEGAKARYOCYTE DERIVATIVES FOR TREATMENT OF DRY EYE DISEASES | Stellular Bio, Inc. (US) | 2025-11-12 | — | — | EP | disclosed |
| US-20250099457-A1 | HETEROARYL-KETONE FUSED AZADECALIN GLUCOCORTICOID RECEPTOR MODULATORS | CORCEPT THERAPEUTICS, INC. (US) | 2025-03-27 | — | — | US | disclosed |
| US-12226412-B2 | Heteroaryl-ketone fused azadecalin glucocorticoid receptor modulators | CORCEPT THERAPEUTICS, INC. (US) | 2025-02-18 | — | — | US | disclosed |
| EP-4434584-A2 | HETEROARYL-KETONE FUSED AZADECALIN GLUCOCORTICOID RECEPTOR MODULATORS | Corcept Therapeutics Incorporated (US) | 2024-09-25 | — | — | EP | disclosed |
| EP-4119561-B1 | HETEROARYL-KETONE FUSED AZADECALIN GLUCOCORTICOID RECEPTOR MODULATORS | CORCEPT THERAPEUTICS INC (US) | 2024-09-11 | — | — | EP | disclosed |
| WO-2024148315-A1 | MEGAKARYOCYTE DERIVATIVES FOR TREATMENT OF DRY EYE DISEASES | STELLULAR BIO, INC. (US) | 2024-07-11 | — | — | WO | disclosed |
| WO-2005037203-A2 | METHODS AND REAGENTS FOR THE TREATMENT OF IMMUNOINFLAMMATORY DISORDERS | COMBINATORX, INCORPORATED (US) | 2005-04-28 | — | — | WO | disclosed |
| WO-2005030132-A2 | THERAPEUTIC REGIMENS FOR ADMINISTERING DRUG COMBINATIONS | COMBINATORX, INCORPORATED (US) | 2005-04-07 | — | — | WO | disclosed |
| WO-2005027839-A2 | METHODS AND REAGENTS FOR THE TREATMENT OF IMMUNOINFLAMMATORY DISORDERS | COMBINATORX, INCORPORATED (US) | 2005-03-31 | — | — | WO | disclosed |
| US-20040229849-A1 | Methods and reagents for the treatment of diseases and disorders associated with increased levels of proinflammatory cytokines | COMBINATORX, INCORPORATED | 2004-11-18 | — | — | US | disclosed |
| US-20040224876-A1 | Combination therapy for the treatment of immunoinflammatory disorders | COMBINATORX, INCORPORATED | 2004-11-11 | — | — | US | disclosed |
| US-20040220153-A1 | Methods and reagents for the treatment of diseases and disorders associated with increased levels of proinflammatory cytokines | COMBINATORX, INCORPORATED | 2004-11-04 | — | — | US | disclosed |
| WO-2004073614-A2 | COMBINATION THERAPY FOR THE TREATMENT OF IMMUNOINFLAMMATORY DISORDERS | COMBINATORX, INCORPORATED (US) | 2004-09-02 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070010502-A1 | Methods and reagents for the treatment of immunoinflammatory disorders | IL5, TPMT, TSLP | SERPINA6 12/4885HSD17B10 2384/4885NR3C1 413/4885 |
| US-20250099457-A1 | HETEROARYL-KETONE FUSED AZADECALIN GLUCOCORTICOID RECEPTOR MODULATORS | NR3C1, GRIN3A, NR3C2 | SERPINA6 143/4885HSD17B10 301/4885NR3C1 1/4885 |
| US-12226412-B2 | Heteroaryl-ketone fused azadecalin glucocorticoid receptor modulators | NR3C1, GRIN3A, NR3C2 | SERPINA6 143/4885HSD17B10 301/4885NR3C1 1/4885 |
| US-20040224876-A1 | Combination therapy for the treatment of immunoinflammatory disorders | HLA-DRB1, TSLP, SERPINA6 | SERPINA6 3/4885HSD17B10 1102/4885NR3C1 132/4885 |
| US-20040220153-A1 | Methods and reagents for the treatment of diseases and disorders associated with increased levels of proinflammatory cytokines | TNF, IL5, IL6 | SERPINA6 13/4885HSD17B10 475/4885NR3C1 31/4885 |
| US-20260124244-A1 | MEGAKARYOCYTE DERIVATIVES FOR TREATMENT OF DRY EYE DISEASES | MYH10, PDGFA, MPL | SERPINA6 894/4885HSD17B10 4379/4885NR3C1 4364/4885 |
| US-20040229849-A1 | Methods and reagents for the treatment of diseases and disorders associated with increased levels of proinflammatory cytokines | TNF, IL5, IL6 | SERPINA6 13/4885HSD17B10 475/4885NR3C1 31/4885 |
| US-20120058979-A1 | METHODS AND REAGENTS FOR THE TREATMENT OF IMMUNOINFLAMMATORY DISORDERS | IL5, TPMT, TSLP | SERPINA6 12/4885HSD17B10 2384/4885NR3C1 413/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.